Samuel S Dychter
Overview
Explore the profile of Samuel S Dychter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dychter S, Harrigan R, Bahn J, Printz M, Sugarman B, DeNoia E, et al.
Clin Ther
. 2014 Feb;
36(2):211-24.
PMID: 24486335
Background: Subcutaneous ondansetron facilitated by recombinant human hyaluronidase PH20 (rHuPH20) is an alternative for treating nausea/vomiting in patients who cannot receive ondansetron by other routes of administration. Objective: Based on...
12.
Dychter S, Gold D, Haller M
J Infus Nurs
. 2012 Apr;
35(3):154-60.
PMID: 22498485
The subcutaneous (SC) route of administration is generally preferred over intravenous administration because it enables at-home injection, improves quality of life, and reduces health care costs. In general, a volume...
13.
Dychter S, Gold D, Carson D, Haller M
J Infus Nurs
. 2012 Mar;
35(2):84-91.
PMID: 22382792
Despite the growing frequency of intravenous (IV) injections, establishing peripheral IV access is challenging, particularly in patients with small or collapsed veins. Therefore, patients often endure failed attempts and eventually...
14.
Desai J, Yassa L, Marqusee E, George S, Frates M, Chen M, et al.
Ann Intern Med
. 2006 Nov;
145(9):660-4.
PMID: 17088579
Background: Sunitinib malate is an oral tyrosine kinase inhibitor recently approved for the treatment of gastrointestinal stromal tumors and renal cell carcinoma. Because the ret proto-oncogene is also inhibited by...